Publication | Closed Access
Gefitinib in Patients with Malignant Mesothelioma: A Phase II Study by the Cancer and Leukemia Group B
256
Citations
15
References
2005
Year
Although 97% of patients with mesothelioma had EGFR overexpression, gefitinib was not active in malignant mesothelioma. EGFR expression does not correlate with failure-free survival.
| Year | Citations | |
|---|---|---|
Page 1
Page 1